Researchers at Vanderbilt-Ingram Cancer Center have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer. Currently, only about 15% of early-stage, triple-negative breast cancer patients benefit from combining immunotherapy, drugs that target immune cells to attack the tumor, with chemotherapy. Identifying why most patients don't respond is critical for personalizing treatment plans and minimizing therapy side effects in patients.

https://www.miragenews.com/immunotherapy-resistant-breast-cancer-new-1097225/

#miragenews